Study: Retina cell breakthrough could help treat blindness
A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.
Study shows high patient satisfaction with AI eye screenings
According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.
Data for aflibercept 8 mg shows durable vision gains at extended dosing intervals for wet AMD
According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.
Euclid founder George Glady passes away at 73
An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.
T. Boone Pickens Foundation donates $20 million to Wilmer Eye Institute, Johns Hopkins Medicine
According to Johns Hopkins Medicine, the gift brings T. Boone Pickens’ total donations to Wilmer to more than $28 million.
ASRS 2023: ZETA-1 phase 2 trial efficacy results for APX3330
David Lally, MD, spoke with our team about the ZETA-1 phase 2 trial efficacy results for APX3330, a novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy at the 2023 ASRS annual meeting.
First investigational eye drop for front and back of the eye met both primary endpoints in Phase 3 OPTIMIZE Trial
Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
ASRS 2023: Long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial
Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.
Ophthalmologists: Castor oil shouldn’t be rubbed in the eyes, no matter what they do on TikTok
Influencers on TikTok claim the vegetable oil promotes eye health. However, ophthalmologists say the risks aren't worth any minimal benefits.
ASRS 2023: Clinical characteristics of macular holes that close without surgery
J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team about clinical characteristics of macular holes that close without surgery at the 2023 ASRS annual meeting.
Kiora Pharmaceuticals, Choroideremia Research Foundation partner to advance novel choroideremia treatment
The partnership will drive Kiora's development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration.
ASRS 2023: The Starlight study
Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.
ASRS 2023: Time to fluid control with faricimab arms complete compared to aflibercept
Aleksandra Rachiskaya, MD, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept at the 2023 ASRS annual meeting.
Iveric Bio receives FDA approval for avacincaptad pegol intravitreal solution for treatment of geographic atrophy
According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.
ASRS 2023: Subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901
Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.
ASRS 2023: Pegcetacoplan vs avacincaptad pegol in patients with geographic atrophy
Paul Hahn, MD, PhD, spoke with our team about comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy at the 2023 ASRS annual meeting.
Study: Dementia more common in older adults with vision issues
Even when wearing their glasses or contact lenses, individuals who scored worse on vision tests were also more likely to have concerning scores on cognitive tests.
ASRS 2023: Outlook Therapeutics and Bevacizumab
Russ Trenary, President and CEO at Outlook Therapeutics spoke with our team to share information on the company's work toward FDA approval for Bevacizumab at the 2023 ASRS annual meeting.
‘Eggsplosions’ and eyes don’t mix
The latest TikTok trend of microwaving hard-boiled eggs and slicing them, causing it to explode, could have ophthalmologists see an influx of injured patients.
ASRS Live: A novel glyco-mimetic nanoparticle for the treatment of geographic atrophy
Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle for the treatment of geographic atrophy at the 2023 ASRS annual meeting.
ASRS Live: Gale extension study
Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study at the 2023 ASRS annual meeting.
CDR-Life, Boehringer Ingelheim announce second milestone achievement in developing antibody fragment-based therapeutics for GA
The companies are partnering to advance a novel therapy with the goal of preserving sight for people living with blinding retinal disease.
VUMC participates in national study to test eye drops for myopia
The Vanderbilt University Medical Center study contradicts earlier studies from East Asia that showed the small dose of atropine is effective in slowing progression of myopia.
ASRS Live: Phaco-buckle-vitrectomy and retinectomy for progressive retinal detachment complicating degenerative retinoschisis
Fernando Arevalo, MD, PhD, FACS, FASRS, spoke with our team to share information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.
ASRS Live: Population pharmacokinetics and safety of OPT-302
Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases at the 2023 ASRS annual meeting.
ASRS Live: 27-Gauge vs 25-gauge vitrectomy for symptomatic vitreous opacities
Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.
ASRS Live: Early treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab
At the 2023 ASRS meeting in Seattle, Washington, Durga Borkar, MD, MMCi, joined our team to discuss the FARETINA-DME study.
ASRS Live: Annexon presents ARCHER trial results highlighting potential of ANX007 as a differentiated treatment for GA
In presentations at the American Society of Retina Specialists 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.
ASRS Live: Apellis providing update on review of safety events with pegcetacoplan injection for GA
During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.
ASRS Live: Presentations and topics at ASRS that are key for retina specialists
Our team spoke with Michael Ip, MD, to get his perspective on the 2023 ASRS meeting in Seattle, Washington and why he thinks these are the most valuable topics to understand and review for retina specialists.
2 Clarke Drive Cranbury, NJ 08512